Trial Profile
Baseline Characteristics and validated safety outcomes of Intravenous Abatacept-Treated Patients with Juvenile Idiopathic Arthritis in a Us Healthcare Claims Database
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2017
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 05 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism